Hasil Pencarian - Devalingam Mahalingam

  • Menampilkan 1 - 9 hasil dari 9
Perbaiki Hasil
  1. 1
    Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

    Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib oleh Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis Giles

    Diterbitkan 2009-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors

    618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L... oleh Syed Kazmi, Lijun Sun, Angela Alistar, Ezra Cohen, Timothy Yap, Devalingam Mahalingam, Justin C Moser, Edward Garmey, Teresa Mooneyham

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

    Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response oleh Andre De Souza, Fabio A. Tavora, Devalingam Mahalingam, Pamela N. Munster, Howard P. Safran, Wafik S. El-Deiry, Wafik S. El-Deiry, Benedito A. Carneiro

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

    First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors oleh Devalingam Mahalingam, Wael Harb, Amita Patnaik, Andrea Bullock, Randolph S. Watnick, Melanie Y. Vincent, Jian Jenny Chen, Suming Wang, Harold Pestana, Judy Chao, James Mahoney, Michael Cieslewicz, Jing Watnick

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    369 Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers

    369 Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomar... oleh Afshin Dowlati, Andrea Bullock, Susanna Ulahannan, Manish Patel, Shubham Pant, Marsha Crochiere, Jian Chen, Devalingam Mahalingam, Mary Mulcahy, Lou Vaickus, Suming Wang, Melanie Vincent, Michael Cieslewicz, Jing Watnick, Dejan Juric, Susanne Fyfe, Randolph Watnick

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors

    651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid... oleh Angela Alistar, Alain Mita, Devalingam Mahalingam, Anthony El-Khoueiry, Jeongjun Kim, Hyunji Ahn, Jinho Choi, Seung-Hee Ryu, Jiye Ahn, Bae Jung Choi, Hwankyu Kang, Yeong-In Yang, Seung-Joo Lee, Borami Jeon, Stefan Proniuk, Kiyean Nam

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    525 Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors

    525 Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors... oleh Hendrik-Tobias Arkenau, Emiliano Calvo, Alain Mita, Young Kwang Chae, Devalingam Mahalingam, Ugur Sahin, Elena Garralda, Oezlem Tuereci, Vladimir Galvao, Stefan Symeonides, Maria Miguel, Hariz Hassan, Annette Baumhauer, Timo Völker, Marie-Cristine Kühnle, Roman Rösemann, Stefan Strobl

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors

    374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors oleh Afshin Dowlati, Andrea Bullock, Susanna Ulahannan, Manish Patel, Shubham Pant, Amita Patnaik, Marsha Crochiere, Devalingam Mahalingam, Wael Harb, Haider Mahdi, Manmeet Ahluwalia, Patrick Wen, Mary Mulcahy, Robert Guttendorf, Lou Vaickus, Suming Wang, Melanie Vincent, Michael Cieslewicz, Jing Watnick

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

    Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors oleh Jian Jenny Chen, Melanie Y. Vincent, Dale Shepard, David Peereboom, Devalingam Mahalingam, James Battiste, Manish R. Patel, Dejan Juric, Patrick Y. Wen, Andrea Bullock, Jennifer Eva Selfridge, Shubham Pant, Joyce Liu, Wendy Li, Susanne Fyfe, Suming Wang, Victor Zota, James Mahoney, Randolph S. Watnick, Michael Cieslewicz, Jing Watnick

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: